TOPLINE: Switching from a boosted protease inhibitor (bPI)–based regimen to bictegravir plus emtricitabine plus tenofovir alafenamide (B/F/TAF) maintained virological suppression over 48 weeks in patients with HIV who had preexisting resistance to nucleoside reverse transcriptase inhibitors (NRTIs), however with increased adverse events. METHODOLOGY: This phase 4 trial assessed the safety and efficacy of switching from […]
The post Switching to Three-Drug Regimen Maintains HIV Suppression first appeared on News Health.
Author : News Health
Publish date : 2025-03-27 11:25:00
Copyright for syndicated content belongs to the linked Source.